Shanghai Fosun Pharmaceutical (Group) (2196.HK) Earnings Analysis

Shanghai Fosun Pharmaceutical (Group) (2196.HK) has no confirmed upcoming earnings date. Last quarter (2026-04-27) it beat with EPS 0.3757 HKD vs 0.02 HKD est (+1778.5%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E 17.96.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 2196.HK next report earnings?

No confirmed upcoming earnings date is currently scheduled for 2196.HK. This page updates as the calendar is published.

2196.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-270.3757 HKD0.02 HKD+1778.5%Beat
2026-03-250.69 HKD0.2898 HKD+138.1%Beat
2025-08-260.701 HKD0.2747 HKD+155.2%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

2196.HK valuation and analyst view

Trailing P/E17.96
Trailing EPS1.317 HKD
Price / book1.27
Dividend yield1.35%
Market cap61.66B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Shanghai Fosun Pharmaceutical (Group) (2196.HK)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 2196.HK. This page updates as the calendar is published.

Did 2196.HK beat earnings last quarter?

In its 2026-04-27 report, 2196.HK posted EPS of 0.3757 HKD versus a 0.02 HKD estimate — a beat of 1778.5%.

What is 2196.HK's earnings track record?

Over the last 3 reported quarters with consensus data, 2196.HK beat estimates 3 times (100%).

What is 2196.HK's current P/E ratio and EPS?

2196.HK trades at a trailing P/E of 17.96 on trailing EPS of 1.3174712863338918 HKD.

What do analysts rate 2196.HK?

2196.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.